Ind-Swift Laboratories Limited (BOM:532305)

Market Cap	10.12B
Revenue (ttm)	5.67B
Net Income (ttm)	2.30B
Shares Out	n/a
EPS (ttm)	31.48
PE Ratio	4.40
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,650
Average Volume	6,386
Open	109.00
Previous Close	107.57
Day's Range	109.00 - 112.90
52-Week Range	67.15 - 151.00
Beta	n/a
RSI	59.28
Earnings Date	Nov 7, 2025

About Ind-Swift Laboratories

Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson’s disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticance...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1995
• Employees: 47
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532305

Financial Performance

In 2024, Ind-Swift Laboratories's revenue was 5.62 billion, a decrease of -56.70% compared to the previous year's 12.97 billion. Earnings were 2.50 billion, a decrease of -40.50%.